Kyle A. Beckwith, MD, PhD

Kittai A.S.; Miller C.; Goldstein D.; Huang Y.; Abruzzo L.V.; Beckwith K.; Bhat S.A.; Bond D.A.; Grever M.R.; Heerema N.A.; Rogers K.A.; Ruppert A.S.; Byrd J.C.; Woyach J.A. 12-09-2021. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treate Blood, 138 23, 2372-2382

Hertlein E.; Beckwith K.A.; Lozanski G.; Chen T.L.; Towns W.H.; Johnson A.J.; Lehman A.; Ruppert A.S.; Bolon B.; Andritsos L.; Lozanski A.; Rassenti L.; Zhao W.; Jarvinen T.M.; Senter L.; Croce C.M.; Symer D.E.; de la Chapelle A.; Heerema N.A.; Byrd J.C. 10-09-2013. Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Viv PLoS ONE, 8 10,

Liu T.M.; Ling Y.; Woyach J.A.; Beckwith K.; Yeh Y.Y.; Hertlein E.; Zhang X.; Lehman A.; Awan F.; Jones J.A.; Andritsos L.A.; Maddocks K.; MacMurray J.; Salunke S.B.; Chen C.S.; Phelps M.A.; Byrd J.C.; Johnson A.J. 08-08-2015. OSU-T315: A novel targeted therapeutic that antagonizes AKT membrane localization and activation of Blood, 125 2, 284-295

Long M.; Beckwith K.; Do P.; Mundy B.L.; Gordon A.; Lehman A.M.; Maddocks K.J.; Cheney C.; Jones J.A.; Flynn J.M.; Andritsos L.A.; Awan F.; Fraietta J.A.; June C.H.; Maus M.V.; Woyach J.A.; Caligiuri M.A.; Johnson A.J.; Muthusamy N.; Byrd J.C. 08-01-2017. Ibrutinib treatment improves T cell number and function in CLL patients Journal of Clinical Investigation, 127 8, 3052-3064

Gensel J.C.; Wang Y.; Guan Z.; Beckwith K.A.; Braun K.J.; Wei P.; McTigue D.M.; Popovich P.G. 07-08-2015. Toll-Like receptors and Dectin-1, a C-type lectin receptor, trigger divergent functions in CNS macro Journal of Neuroscience, 35 27, 9966-9976

Do P.; Beckwith K.A.; Cheney C.; Tran M.; Beaver L.; Griffin B.G.; Mo X.; Liu Y.; Lapalombella R.; Hertlein E.; Muthusamy N.; Byrd J.C. 05-01-2019. Leukemic B cell CTLA-4 suppresses costimulation of T cells Journal of Immunology, 202 9, 2806-2816

Fraietta J.A.; Beckwith K.A.; Patel P.R.; Ruella M.; Zheng Z.; Barrett D.M.; Lacey S.F.; Melenhorst J.J.; McGettigan S.E.; Cook D.R.; Zhang C.; Xu J.; Do P.; Hulitt J.; Kudchodkar S.B.; Cogdill A.P.; Gill S.; Porter D.L.; Woyach J.A.; Long M.; Johnson A.J.; Maddocks K.; Muthusamy N.; Levine B.L.; June C.H.; Byrd J.C.; Maus M.V. 03-03-2016. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia Blood, 127 9, 1117-1127

Kittai A.S.; Huang Y.; Beckwith K.A.; Bhat S.A.; Bond D.A.; Byrd J.C.; Goldstein D.; Grever M.R.; Miller C.; Rogers K.A.; Yano M.; Woyach J.A. 01-01-2023. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic l American Journal of Hematology, 98 1, 56-65

Beckwith K.; Byrd J.; Muthusamy N. 01-01-2015. Tetraspanins as therapeutic targets in hematological malignancy: A concise review Frontiers in Physiology, 6 MAR,

Hing Z.A.; Mantel R.; Beckwith K.A.; Guinn D.; Williams E.; Smith L.L.; Williams K.; Johnson A.J.; Lehman A.M.; Byrd J.C.; Woyach J.A.; Lapalombella R. 01-01-2015. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic Blood, 125 20, 3128-3132

Beckwith K.A.; Frissora F.W.; Stefanovski M.R.; Towns W.H.; Cheney C.; Mo X.; Deckert J.; Croce C.M.; Flynn J.M.; Andritsos L.A.; Jones J.A.; Maddocks K.J.; Lozanski G.; Byrd J.C.; Muthusamy N. 01-01-2014. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel Leukemia, 28 7, 1501-1510

Zhong Y.; El-Gamal D.; Dubovsky J.A.; Beckwith K.A.; Harrington B.K.; Williams K.E.; Goettl V.M.; Jha S.; Mo X.; Jones J.A.; Flynn J.M.; Maddocks K.J.; Andritsos L.A.; McCauley D.; Shacham S.; Kauffman M.; Byrd J.C.; Lapalombella R. 01-01-2014. Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chron Leukemia, 28 5, 1158-1163

Dubovsky J.A.; Beckwith K.A.; Natarajan G.; Woyach J.A.; Jaglowski S.; Zhong Y.; Hessler J.D.; Liu T.M.; Chang B.Y.; Larkin K.M.; Stefanovski M.R.; Chappell D.L.; Frissora F.W.; Smith L.L.; Smucker K.A.; Flynn J.M.; Jones J.A.; Andritsos L.A.; Maddocks K.; Lehman A.M.; Furman R.; Sharman J.; Mishra A.; Caligiuri M.A.; Satoskar A.R.; Buggy J.J.; Muthusamy N.; Johnson A.J.; Byrd J.C. 01-01-2013. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lympho Blood, 122 15, 2539-2549